MONTGOMERY, Ala.--(BUSINESS WIRE)--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses and markets niche prescription products, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission of its New Drug Application for PRO-513 for the treatment of migraine headaches. In accordance with the Prescription Drug User Fee Act (PDUFA), the FDA has set the goal date for their review as July 27, 2008.
